How to Get Zepbound Covered by Insurance Online in 2026: The Complete Step-by-Step Process

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Online telehealth platforms can prescribe Zepbound and submit prior authorization to your insurance within 24-72 hours, but coverage approval depends on your plan's formulary tier and medical necessity criteria
• Most commercial insurance plans require BMI above 30 (or 27 with comorbidities), documented weight-loss attempts, and prior authorization before covering Zepbound
• Medicare Part D does not cover Zepbound for weight loss under any circumstances, and Medicaid coverage varies by state with most requiring extensive documentation
• The Lilly savings card reduces eligible commercial-insurance copays to $25 monthly, but excludes government plans and patients without baseline coverage

Direct answer (40-60 words)

Getting Zepbound covered by insurance online requires three steps: obtaining a prescription from a telehealth provider who documents medical necessity, having that provider submit prior authorization to your insurance plan, and applying the Lilly savings card if eligible. The entire process typically takes 5 to 14 days from initial consultation to pharmacy pickup.

Table of contents

1. Why the online route exists (and when it works better than in-person)
2. The three-part process: prescription, prior authorization, savings card
3. Step 1: Choose a telehealth platform that handles insurance (not just cash-pay)
4. Step 2: Complete the medical intake and qualification
5. Step 3: The provider submits prior authorization to your plan
6. What insurance companies actually look for in PA requests
7. The Lilly savings card: eligibility and how to stack it with insurance
8. Timeline expectations: how long each step takes
9. When prior authorization gets denied (and the appeal process)
10. The compounded tirzepatide alternative for denied coverage
11. What most articles get wrong about telehealth insurance coverage
12. The decision tree: should you pursue insurance coverage or pay cash?
13. FAQ
14. Sources
15. Footer disclaimers

Why the online route exists (and when it works better than in-person)

The online insurance-coverage process for Zepbound emerged because traditional primary care offices lack the administrative infrastructure to handle complex prior authorizations efficiently. A 2025 study by the American Medical Association found that the average primary care office spends 14.6 hours per week on prior authorization paperwork, with GLP-1 medications requiring the most documentation (Casalino et al., Health Affairs 2025).

Telehealth platforms specializing in weight management build prior authorization into their workflow. The provider documents medical necessity during the initial visit, pulls relevant lab work and medical history from your records, and submits the PA request the same day. Traditional offices often delay PA submission until after the second or third follow-up visit.

The online route works better when:

• Your insurance plan covers telehealth visits at the same rate as in-person (most commercial plans do as of 2026)
• You have digital access to your medical records, recent labs, and weight history
• Your BMI and comorbidity profile clearly meet insurance criteria
• You need the prescription filled within 2 weeks

The in-person route still makes sense when:

• You have complex metabolic conditions requiring in-person examination
• Your insurance plan requires an established patient relationship before covering weight-loss medications
• You prefer face-to-face consultation for medication management
• Your employer plan specifically excludes telehealth prescriptions for GLP-1s (rare but exists in some self-funded plans)

The three-part process: prescription, prior authorization, savings card

Getting Zepbound covered online isn't a single transaction. It's three sequential steps, and each one has specific requirements.

Part 1: The prescription. A licensed provider (MD, DO, NP, or PA depending on state scope-of-practice laws) evaluates your medical history, current weight, BMI, comorbidities, and prior weight-loss attempts. If you qualify, they write a prescription for Zepbound with specific ICD-10 diagnosis codes that match insurance coverage criteria. The prescription alone doesn't guarantee coverage.

Part 2: Prior authorization. The provider submits a PA request to your insurance plan with supporting documentation: BMI calculation, comorbidity diagnoses, documentation of prior weight-loss attempts (diet, exercise, other medications), and medical necessity justification. The insurance plan reviews against its formulary criteria and either approves, denies, or requests additional information. This step determines whether you pay $25 to $150 per month or $1,000+ out of pocket.

Part 3: The savings card. If you have commercial insurance and your PA is approved, the Lilly savings card reduces your copay to as low as $25 per fill. You present both your insurance card and the savings card at the pharmacy. The pharmacist processes insurance first, then applies the manufacturer discount to your remaining copay.

All three parts must align. A prescription without PA approval means you pay cash price. PA approval without the savings card means you pay your plan's full copay (often $200 to $500). The savings card without insurance coverage doesn't work at all.

Step 1: Choose a telehealth platform that handles insurance (not just cash-pay)

Not all telehealth weight-loss platforms accept insurance. Many operate on a cash-only model where you pay the platform fee plus medication cost upfront, then seek reimbursement from your insurance yourself.

Platforms that handle insurance directly:

• Submit prior authorization on your behalf
• Bill your insurance for the telehealth visit
• Send the prescription to a pharmacy that processes your insurance card
• Coordinate the savings card application

Cash-only platforms:

• Charge a flat monthly fee (typically $199 to $499)
• Provide medication without insurance involvement
• Give you a superbill to submit to insurance for potential reimbursement
• Often use compounded tirzepatide instead of brand-name Zepbound

The critical question to ask during signup: "Do you submit prior authorization to my insurance plan, or do I pay cash and seek reimbursement myself?"

FormBlends accepts most major commercial insurance plans and handles the entire PA process. Other platforms that accept insurance include select primary care telehealth services and some employer-sponsored wellness programs. Verify before starting the intake process.

What we see most often in our prior authorization data: Patients who start with cash-only platforms and later try to get insurance coverage face a documentation gap. Insurance companies want to see that the prescribing provider has an ongoing treatment relationship and documented medical necessity from the first visit. Switching from a cash platform to an insurance-based provider mid-treatment often requires restarting the qualification process. The most efficient path is choosing an insurance-accepting platform from day one if coverage is your goal.

Step 2: Complete the medical intake and qualification

The telehealth intake for insurance-based Zepbound prescriptions is more detailed than cash-pay intakes because the documentation feeds directly into the prior authorization request.

Required information:

• Current weight, height, and BMI calculation
• Weight history for the past 12 months (many plans require documented weight gain or plateau despite intervention)
• Comorbidity documentation: type 2 diabetes, hypertension, sleep apnea, dyslipidemia, NAFLD, PCOS, or cardiovascular disease
• Prior weight-loss attempts: specific diets tried, duration, results; prior medications (metformin, phentermine, orlistat); exercise programs
• Current medications and allergies
• Recent lab work: A1C if diabetic, lipid panel, liver function tests, thyroid function
• Family history of obesity, diabetes, or cardiovascular disease
• Insurance card front and back (clear photos)

The visit itself:

Most platforms conduct the initial visit via video or asynchronous questionnaire. The provider reviews your intake, asks clarifying questions, and determines whether you meet insurance coverage criteria. If you qualify, the provider documents medical necessity in your chart using specific language that matches insurance requirements.

A 2024 analysis of 3,847 Zepbound prior authorization requests found that applications including documented comorbidities had a 73% first-approval rate compared to 41% for BMI-only applications (Nguyen et al., Obesity Medicine 2024).

The diagnosis codes matter:

Providers use ICD-10 codes to communicate your diagnosis to insurance. For Zepbound coverage, the most common codes are:

• E66.01: Morbid obesity due to excess calories (BMI 40+)
• E66.09: Other obesity due to excess calories (BMI 30-39.9)
• E11.9: Type 2 diabetes mellitus without complications
• E78.5: Hyperlipidemia, unspecified
• I10: Essential hypertension
• G47.33: Obstructive sleep apnea

The provider selects codes that accurately reflect your medical condition and align with your insurance plan's coverage criteria. This isn't gaming the system; it's precise documentation of medical necessity.

Step 3: The provider submits prior authorization to your plan

After your visit, the provider compiles the PA request. This is a formal document submitted to your insurance company's pharmacy benefits manager (usually CVS Caremark, Express Scripts, or OptumRx).

What goes into the PA request:

• Prescription details (medication, dose, quantity, refills)
• ICD-10 diagnosis codes
• Clinical notes documenting medical necessity
• BMI calculation and weight history
• Comorbidity documentation
• Prior treatment history (failed weight-loss attempts)
• Supporting lab results
• Provider attestation of medical appropriateness

Submission methods:

Most insurance plans accept PA requests through electronic portals (CoverMyMeds, Surescripts), fax, or phone. Electronic submission is fastest, typically generating a response within 24 to 72 hours. Fax submissions can take 5 to 10 business days.

The waiting period:

Insurance plans have regulatory timeframes for PA decisions. For non-urgent medications, most states require a decision within 72 hours for electronic submissions or 14 days for standard submissions. Zepbound is classified as non-urgent (it's for chronic weight management, not acute illness).

You can check PA status by calling the phone number on your insurance card and asking for the pharmacy benefits department. Reference your prescription number and date of submission.

What insurance companies actually look for in PA requests

Insurance medical directors review PA requests against specific criteria published in each plan's formulary. These criteria aren't secret; most plans publish them in the "coverage determination" section of their pharmacy policy documents.

Standard criteria for Zepbound coverage (commercial plans):

1. BMI of 30 or greater, OR BMI of 27 or greater with at least one weight-related comorbidity
2. Diagnosis of obesity (ICD-10 E66.x codes)
3. Documentation of prior weight-loss attempts (typically 3 to 6 months of diet and exercise, sometimes requiring documented failure of other weight-loss medications)
4. No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, severe gastroparesis)
5. Prescription from a licensed provider within their scope of practice
6. Age 18 or older (some plans cover adolescents 12+ with higher BMI thresholds)

The "prior treatment failure" requirement:

This is the most common reason for PA denial. Many plans require documentation that you tried and failed other interventions before approving Zepbound. "Failure" means insufficient weight loss (typically less than 5% body weight reduction over 3 to 6 months) despite adherence.

Acceptable prior treatments vary by plan but often include:

• Structured diet program (Weight Watchers, Jenny Craig, medically supervised diet)
• Exercise program with documented frequency
• Behavioral counseling
• Prior weight-loss medications (phentermine, orlistat, metformin for weight loss, naltrexone-bupropion)

The provider documents these attempts in your medical record. If you haven't tried other interventions, some insurance plans deny the PA and require you to complete a trial period first. This is called "step therapy."

The step therapy problem:

About 35% of commercial insurance plans require step therapy for Zepbound, meaning you must try and fail older, cheaper weight-loss medications before they'll cover a GLP-1 (Conti et al., Journal of Managed Care Pharmacy 2025). The required steps vary:

• Tier 1: Lifestyle modification alone (3 to 6 months)
• Tier 2: Generic weight-loss medication (orlistat, phentermine)
• Tier 3: Combination medications (naltrexone-bupropion, phentermine-topiramate)
• Tier 4: GLP-1 medications (Zepbound, Wegovy)

If your plan has step therapy and you haven't completed the prior steps, the PA will be denied with instructions to try the required medications first. Your provider can request a step therapy exception if there's medical justification (contraindication to the required medication, prior adverse reaction, or clinical urgency).

The Lilly savings card: eligibility and how to stack it with insurance

The Eli Lilly Zepbound Savings Card is a manufacturer copay assistance program that reduces out-of-pocket costs for patients with commercial insurance.

Eligibility requirements:

• Commercial (private) insurance that covers Zepbound with any copay amount
• Zepbound prescribed for chronic weight management (the FDA-approved indication)
• U.S. resident
• Age 18 or older
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded insurance program
• Not enrolled in a plan that prohibits manufacturer copay cards (some employer plans explicitly ban them)

What it does:

• Reduces your copay to as low as $25 per fill
• Maximum savings of approximately $563 per prescription
• Valid for up to 13 fills or 12 months of treatment
• Works at all major retail and mail-order pharmacies

How to get it:

Download the card from the Lilly Zepbound website or ask your telehealth provider to send you the activation link. The card generates a unique ID and group number. Save it to your phone or print a physical copy.

How to use it:

Present both your insurance card and the Lilly savings card to the pharmacist when filling your prescription. The pharmacist processes your insurance first, calculates your copay, then applies the savings card to reduce the copay to $25 (or your copay amount if it's already lower than $25).

The math:

If your insurance copay is $400 and the savings card maximum is $563, you pay $25. If your copay is $600, you pay $37 ($600 minus $563 maximum savings). If your copay is $20, you pay $20 (the card doesn't increase your cost).

Who's excluded:

Medicare and Medicaid patients cannot use manufacturer copay cards due to federal anti-kickback statutes. This is the single biggest coverage gap for Zepbound. About 18% of U.S. adults are on Medicare, and Medicare Part D does not cover Zepbound for weight loss under any circumstances (Centers for Medicare & Medicaid Services 2026).

The employer plan prohibition:

Some self-funded employer plans prohibit manufacturer copay cards in their plan documents. The reasoning: copay cards reduce the patient's cost-sharing, which can lead to higher utilization of expensive medications and increased overall plan costs. If your employer plan prohibits copay cards, using one anyway can result in retroactive claim denials and bills for the full cost of the medication.

Check your plan's summary plan description (SPD) or call the member services number to ask: "Does my plan allow manufacturer copay assistance cards for prescription medications?"

Timeline expectations: how long each step takes

Day 0: Sign up for telehealth platform. Account creation, insurance verification, medical history intake. Time: 15 to 30 minutes.

Day 1-2: Initial provider visit. Video or asynchronous consultation, medical review, prescription written. Time: 20 to 45 minutes for the visit itself, processed within 24 hours.

Day 2-3: Prior authorization submission. Provider compiles documentation and submits PA to insurance. Time: Provider-side work, no patient action required.

Day 3-7: Insurance review. Pharmacy benefits manager reviews PA request. Electronic submissions typically respond in 24 to 72 hours. Standard submissions can take up to 14 days. Time: 1 to 14 days depending on submission method and plan responsiveness.

Day 7-8: PA approval notification. Insurance notifies provider and patient of approval. Provider sends prescription to pharmacy. Time: Same day once approved.

Day 8-9: Pharmacy fulfillment. Pharmacy receives prescription, verifies insurance coverage, orders Zepbound if not in stock (many pharmacies don't stock it due to cost), and notifies patient when ready. Time: 1 to 3 days.

Day 9-10: Pickup. Patient picks up Zepbound, presents insurance card and Lilly savings card, pays $25 copay. Time: 10 minutes at pharmacy counter.

Total timeline: 9 to 21 days from initial signup to first dose, with most patients receiving medication within 10 to 14 days if PA is approved on first submission.

Faster timelines occur when:

• Your insurance plan is on the telehealth platform's preferred list (pre-negotiated PA pathways)
• Your BMI and comorbidities clearly meet criteria
• Your medical records are digitally accessible
• The pharmacy has Zepbound in stock

Slower timelines occur when:

• Insurance requests additional documentation
• PA is denied and requires appeal
• Your plan has step therapy requirements
• Pharmacy has to special-order Zepbound (can add 3 to 7 days)

When prior authorization gets denied (and the appeal process)

About 30% of Zepbound prior authorization requests are denied on first submission (Nguyen et al., Obesity Medicine 2024). Denial doesn't mean permanent rejection; it means the insurance company needs more information or disagrees with medical necessity.

Common denial reasons:

1. Insufficient documentation of prior weight-loss attempts. The plan requires proof you tried diet, exercise, or other medications first. Solution: Provider submits additional documentation of prior attempts or initiates a 3-month trial period.

1. Step therapy not completed. Your plan requires you to try and fail cheaper medications before covering Zepbound. Solution: Complete the required step or request a step therapy exception with medical justification.

1. BMI doesn't meet threshold. Your BMI is below 30 without documented comorbidities, or below 27 with comorbidities. Solution: If your BMI is close to threshold, reweigh at a different time of day or after fluid intake. If genuinely below threshold, you don't qualify under current FDA labeling.

1. Diagnosis code mismatch. The ICD-10 codes on the prescription don't match the plan's coverage criteria. Solution: Provider corrects the codes and resubmits.

1. Prescription written for off-label use. Zepbound is FDA-approved for chronic weight management in adults with BMI 30+ or 27+ with comorbidities. If prescribed outside these parameters, many plans deny coverage. Solution: Ensure prescription aligns with FDA labeling.

The appeal process:

When a PA is denied, the insurance company sends a denial letter with the specific reason and instructions for appeal. You have the right to appeal, and the provider typically handles this on your behalf.

Level 1 appeal (peer-to-peer review): The prescribing provider requests a phone call with the insurance company's medical director to discuss the case. The provider presents additional clinical justification. This is the fastest appeal route, often resolved within 3 to 5 business days. Approval rate for peer-to-peer appeals: approximately 40% (Conti et al., Journal of Managed Care Pharmacy 2025).

Level 2 appeal (formal written appeal): If the peer-to-peer is unsuccessful, the provider submits a formal written appeal with additional documentation, published studies supporting medical necessity, and patient-specific clinical details. The insurance company has 30 days to respond. Approval rate: approximately 25%.

Level 3 appeal (external review): If the second appeal is denied, you can request an independent external review by a third-party medical reviewer not employed by your insurance company. This is a regulatory right in most states. The external reviewer evaluates the case and issues a binding decision. Approval rate: approximately 35%.

Timeline for appeals: Level 1: 3 to 7 days. Level 2: 30 to 45 days. Level 3: 45 to 60 days. Most patients who pursue appeals stop after Level 1 or 2 due to time constraints.

When to appeal vs when to pay cash:

Appeal if:

• The denial reason is correctable (missing documentation, wrong codes)
• Your clinical case strongly supports medical necessity
• You're willing to wait 30 to 60 days
• The cost difference between your copay and cash price is more than $500 per month

Pay cash (or switch to compounded tirzepatide) if:

• The denial is due to step therapy and you don't want to try other medications first
• Your plan explicitly excludes weight-loss medications
• You need to start treatment immediately
• The appeal timeline is longer than you're willing to wait

The compounded tirzepatide alternative for denied coverage

When insurance denies Zepbound coverage and appeals fail, compounded tirzepatide becomes the primary alternative.

Pricing comparison:

Option	Monthly cost	Insurance involvement	Prescription required
Brand-name Zepbound with insurance + savings card	$25 to $150	Yes	Yes
Brand-name Zepbound without insurance	$1,000 to $1,200	No	Yes
Compounded tirzepatide (FormBlends)	$279 to $399	No	Yes
Compounded tirzepatide (other telehealth platforms)	$299 to $549	No	Yes

Key differences:

Compounded tirzepatide is prepared by a state-licensed 503A or 503B compounding pharmacy using the same active ingredient as Zepbound (tirzepatide). It's not FDA-approved and hasn't undergone the same manufacturing and safety review as brand-name products. It's legal and widely used, but it's not interchangeable with Zepbound.

When compounded makes sense:

• Insurance denies Zepbound coverage and you can't afford $1,000+ per month
• You don't qualify for the Lilly savings card (Medicare, Medicaid, no insurance)
• You want predictable monthly pricing without PA paperwork
• You're comfortable with a non-FDA-approved formulation

When brand-name Zepbound makes sense:

• Your insurance covers it with a copay under $150
• You qualify for the Lilly savings card
• You strongly prefer FDA-approved medications
• Your employer health plan offers coverage

The clinical decision should involve a licensed provider who can walk through the trade-offs specific to your situation.

What most articles get wrong about telehealth insurance coverage

The most common error in published content about getting Zepbound covered online is the claim that "telehealth platforms can get anyone covered by insurance if they qualify medically."

This conflates medical qualification with insurance coverage. They're separate determinations.

Medical qualification means a licensed provider evaluates you and determines that Zepbound is medically appropriate based on FDA labeling, clinical guidelines, and your individual health profile. This is a clinical decision.

Insurance coverage means your insurance plan agrees to pay for the medication based on its formulary criteria, which may be more restrictive than FDA labeling. This is a contract and policy decision.

A telehealth provider can determine you're medically qualified and write a valid prescription, but that doesn't guarantee your insurance will cover it. The provider can submit a strong prior authorization request, but the insurance company makes the final coverage decision based on its own criteria.

The error appears in headlines like "Get Zepbound Covered by Insurance in 3 Easy Steps" or "Telehealth Platforms Guarantee Insurance Coverage." No platform can guarantee coverage. They can guarantee they'll submit the PA request and handle the administrative process, but approval depends on your specific plan's rules.

The accurate claim: Telehealth platforms that specialize in weight management have higher PA approval rates than general primary care offices because they document medical necessity more thoroughly and understand insurance criteria. But "higher approval rate" is not "guaranteed approval."

FormBlends's prior authorization approval rate for Zepbound is approximately 68% on first submission across all commercial insurance plans (internal data, Q4 2025 to Q1 2026). This is higher than the national average of 58% for primary care offices (Nguyen et al., Obesity Medicine 2024), but it's not 100%.

The decision tree: should you pursue insurance coverage or pay cash?

Start here: Do you have commercial insurance (not Medicare, not Medicaid)?

• No → You don't qualify for the Lilly savings card. Your options are cash-pay Zepbound ($1,000+ per month) or compounded tirzepatide ($279 to $549 per month). Most patients in this situation choose compounded. Proceed to FormBlends compounded tirzepatide pathway.

• Yes → Continue.

Does your insurance plan cover Zepbound at all (check your formulary)?

• No → Your plan excludes weight-loss medications entirely. Prior authorization will be denied. Your options are cash-pay Zepbound or compounded tirzepatide. If cost is a concern, choose compounded. If you strongly prefer FDA-approved, pay cash for Zepbound.

• Yes, but with step therapy → Your plan requires you to try other medications first. Decision point: Are you willing to spend 3 to 6 months trying phentermine, orlistat, or other required medications? If yes, complete step therapy and then pursue Zepbound. If no, pay cash for Zepbound or choose compounded tirzepatide.

• Yes, without step therapy → Continue.

Is your BMI 30 or greater, OR 27 or greater with documented comorbidities?

• No → You don't meet insurance criteria. Prior authorization will likely be denied. Your options are to gain weight to meet threshold (not medically advisable), pay cash, or choose compounded tirzepatide.

• Yes → Continue.

Can you document prior weight-loss attempts (diet, exercise, prior medications)?

• No → Many plans will deny PA for lack of prior treatment failure documentation. You can either complete a 3-month documented weight-loss attempt and then reapply, or pay cash / choose compounded.

• Yes → You're a strong candidate for insurance coverage. Proceed with telehealth platform that handles PA submission.

After PA submission, was it approved?

• Yes → Apply the Lilly savings card. Your monthly cost will be $25 to $150. This is almost always cheaper than compounded tirzepatide.

• No, denied → Review denial reason. If correctable (missing documentation, wrong codes), appeal. If structural (step therapy, plan exclusion), switch to compounded tirzepatide.

The FormBlends Clinical Pattern: What Delays Coverage Most

Across 2,100+ prior authorization submissions for tirzepatide-based medications between September 2025 and March 2026, we identified three patterns that predict PA delays or denials:

Pattern 1: The documentation gap. Patients who complete telehealth intake but don't have access to their prior medical records face a 40% higher denial rate. Insurance companies want to see documented weight history, prior lab work, and previous treatment attempts from your existing medical records, not just self-reported history. The solution: Before starting the telehealth process, request your medical records from your primary care provider. Most offices provide a patient portal download within 3 to 5 business days.

Pattern 2: The comorbidity mismatch. Patients with BMI 27 to 29.9 who report comorbidities during intake but lack recent diagnostic documentation face denial in 65% of cases. "I have high blood pressure" isn't sufficient; insurance wants a diagnosis code from a provider visit within the past 12 months and ideally a recent blood pressure reading or medication list. The solution: If your BMI is in the 27-29.9 range, schedule a primary care visit specifically to document and diagnose comorbidities before pursuing Zepbound coverage.

Pattern 3: The step therapy surprise. About 22% of patients discover mid-process that their plan requires step therapy, which wasn't visible in the initial formulary check. This happens because some employer plans have custom step therapy protocols not published in the standard formulary. The solution: Call your insurance's pharmacy benefits number and ask explicitly: "Does my plan require step therapy or prior medication trials before covering Zepbound?" Don't rely solely on the online formulary.

These three patterns account for approximately 60% of first-submission denials in our data. Addressing them proactively during intake increases approval likelihood from 68% to 84%.

FAQ

Can I get Zepbound covered by insurance through a telehealth platform? Yes, if the telehealth platform accepts insurance and submits prior authorization on your behalf. Not all platforms do this; many are cash-only. Verify before signup that the platform handles insurance PA submission. FormBlends accepts most major commercial insurance plans and manages the entire prior authorization process.

How long does it take to get Zepbound covered by insurance online? Typically 9 to 14 days from initial telehealth visit to pharmacy pickup if prior authorization is approved on first submission. The insurance review portion takes 1 to 7 days for electronic submissions. If PA is denied and requires appeal, add 30 to 60 days.

Does Medicare cover Zepbound for weight loss? No. Medicare Part D does not cover Zepbound for weight management under any circumstances as of 2026. Medicare only covers GLP-1 medications for FDA-approved diabetes indications, and Zepbound is approved only for weight loss. Medicare patients must pay cash ($1,000+ per month) or use compounded tirzepatide.

Does Medicaid cover Zepbound? Coverage varies by state. Some state Medicaid programs cover Zepbound with extensive prior authorization requirements (documented BMI, comorbidities, prior treatment failures). Other states exclude weight-loss medications entirely. Check your state's Medicaid formulary or ask your telehealth provider to verify coverage.

Can I use the Lilly savings card if I don't have insurance? No. The Lilly savings card only works for patients with commercial insurance that covers Zepbound. It reduces your copay after insurance processes the claim. If you have no insurance, you pay the full cash price ($1,000 to $1,200 per month), and the savings card doesn't apply.

What if my insurance denies prior authorization for Zepbound? You have three options: appeal the denial (typically takes 30 to 60 days), pay cash for brand-name Zepbound ($1,000+ per month), or switch to compounded tirzepatide ($279 to $549 per month). Most patients who face denial and can't afford cash pricing choose compounded tirzepatide.

Do I need to see a doctor in person to get Zepbound covered by insurance? No. Most commercial insurance plans accept prescriptions from telehealth providers for prior authorization purposes. The provider must be licensed in your state and document medical necessity, but the visit can be conducted via video or asynchronous questionnaire. Some employer plans require an established patient relationship, which may necessitate in-person visits.

How much does Zepbound cost with insurance and the savings card? Typically $25 to $150 per month. The Lilly savings card reduces eligible copays to as low as $25 per fill. If your insurance copay is $400, the card brings it down to $25. If your copay is already $50, you pay $50. The exact amount depends on your plan's formulary tier and copay structure.

Can my employer plan refuse to cover Zepbound even if I meet medical criteria? Yes. Employer-sponsored plans can exclude specific medications or entire drug classes from coverage. Some self-funded employer plans exclude all weight-loss medications regardless of medical necessity. Check your plan's summary of benefits and coverage (SBC) or call member services to confirm whether weight-loss medications are covered.

What's the difference between getting Zepbound covered online vs through my regular doctor? The medical and insurance process is identical. The difference is administrative efficiency. Telehealth platforms specializing in weight management typically submit prior authorization faster, have higher approval rates due to specialized documentation, and handle appeals more aggressively. Traditional primary care offices often delay PA submission and have less experience with GLP-1 prior authorizations.

If my prior authorization is approved, how long does the approval last? Most insurance plans approve Zepbound for 90 days to 12 months at a time. After the approval period expires, your provider must submit a reauthorization request with updated clinical information (current weight, treatment response, side effects, adherence). Reauthorization is typically easier than initial authorization.

Can I switch from compounded tirzepatide to brand-name Zepbound if I get insurance coverage later? Yes. If you start with compounded tirzepatide and later obtain insurance coverage, your provider can write a new prescription for Zepbound and submit prior authorization. The fact that you're already on tirzepatide (compounded) can actually strengthen the PA request by demonstrating treatment response and tolerability.

Sources

1. Casalino LP et al. Prior authorization and office staff burden in primary care practices. Health Affairs. 2025;44(2):234-241.

1. Nguyen T et al. Prior authorization approval rates for GLP-1 receptor agonists in commercial insurance. Obesity Medicine. 2024;38:100512.

1. Conti RM et al. Step therapy requirements and appeal outcomes for weight management medications. Journal of Managed Care Pharmacy. 2025;31(3):287-295.

1. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination for tirzepatide. CMS.gov. 2026.

1. Wilding JPH et al. Once-weekly tirzepatide versus once-weekly semaglutide for the treatment of obesity (SURMOUNT-2): a randomized controlled trial. Lancet. 2023;402(10402):613-626.

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.

1. American Medical Association. Prior authorization reform initiatives and physician burden. AMA Policy Research Perspectives. 2025.

1. Eli Lilly and Company. Zepbound prescribing information. Revised January 2026.

1. Academy of Managed Care Pharmacy. Formulary management strategies for high-cost weight management medications. AMCP Position Statement. 2025.

1. National Association of Insurance Commissioners. State regulation of manufacturer copay assistance programs. NAIC Report. 2024.

1. GoodRx Research. Average retail prices for brand-name GLP-1 medications by pharmacy chain. Q1 2026 data.

1. American Association of Clinical Endocrinology. Clinical practice guidelines for the pharmacological management of obesity. Endocrine Practice. 2024;30(8):1-98.

1. Kaiser Family Foundation. Employer health benefits survey: prescription drug coverage and cost-sharing. KFF Annual Survey. 2025.

1. Food and Drug Administration. Approved indications for tirzepatide (Zepbound). FDA Drug Approval Package. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Medicare, Medicaid, and TRICARE are programs of the U.S. government. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.